Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pidnarulex - Senhwa Biosciences

Next Previous
Drug Profile

Pidnarulex - Senhwa Biosciences

Alternative Names: CX-5461

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cylene Pharmaceuticals
  • Developer BC Cancer Research Centre; Canadian Cancer Trials Group; Peter MacCallum Cancer Centre; Senhwa Biosciences
  • Class Amides; Antineoplastics; Heterocyclic compounds with 4 or more rings; Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action G-Quadruplex modulators; RNA polymerase I inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Haematological malignancies; Ovarian cancer
  • Phase I/II Solid tumours
  • Phase I Prostate cancer

Most Recent Events

  • 25 Jun 2025 Pidnarulex - Senhwa Biosciences is available for licensing as of 25 Jun 2025. http://www.bio-thera.com
  • 25 Jun 2025 Senhwa Biosciences announces intention to submit IND for colorectal cancer, breast cancer and lymphoma
  • 25 Jun 2025 Senhwa Biosciences plans a clinical trial for colorectal cancer, breast cancer and lymphoma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top